2024-514265-19-00CompletedPhase 1
Single Ascending Dose study of ENX-104
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Dec 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 3 Jun 2024
- Start date
- 17 Jul 2024
- Lead sponsor
- Engrail Therapeutics Inc.
- Diseases
- Depression
- EU CT number
- 2024-514265-19-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.